VMD Valuation
Viemed Healthcare Inc
$
6.760
- Overview
- Forecast
- Valuation
VMD Relative Valuation
VMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VMD is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for VMD's competitors is 0.42, providing a benchmark for relative valuation. Viemed Healthcare Inc Corp (VMD) exhibits a P/S ratio of 0.99, which is 134.31% above the industry average. Given its robust revenue growth of 16.87%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
PDLB
Ponce Financial Group Inc
13.770
USD
-1.08%
TATT
TAT Technologies Ltd
34.640
USD
-1.62%
PBPB
Potbelly Corp
10.230
USD
-0.10%
TTSH
Tile Shop Holdings Inc
6.100
USD
+0.33%
XOMA
XOMA Corp
26.990
USD
+0.33%
TSHA
Taysha Gene Therapies Inc
2.700
USD
+5.47%
LFVN
LifeVantage Corp
13.390
USD
+6.19%
MVIS
MicroVision Inc
1.120
USD
+4.67%
GOCO
Gohealth Inc
7.130
USD
-1.66%
MPX
Marine Products Corp
8.880
USD
-0.67%
FAQ
Is Viemed Healthcare Inc (VMD) currently overvalued or undervalued?
Viemed Healthcare Inc (VMD) is now in the Undervalued zone, suggesting that its current forward PE ratio of 17.79 is considered Undervalued compared with the five-year average of 28.70. The fair price of Viemed Healthcare Inc (VMD) is between 6.87 to 12.07 according to relative valuation methord. Compared to the current price of 6.76 USD , Viemed Healthcare Inc is Undervalued By 1.65% .
What is Viemed Healthcare Inc (VMD) fair value?
How does VMD's valuation metrics compare to the industry average?
What is the current P/B ratio for Viemed Healthcare Inc (VMD) as of May 19 2025?
What is the current FCF Yield for Viemed Healthcare Inc (VMD) as of May 19 2025?
What is the current Forward P/E ratio for Viemed Healthcare Inc (VMD) as of May 19 2025?